PRESS RELEASE
23rd June 2008
ISO 17025 Accreditation for Forensic Toxicology and Therapeutic Pharmacological Analysis
Eurofins Forensic Services, part of Eurofins Scientific, is pleased to announce the accreditation of its specialist partner laboratory to ISO 17025 for the analysis of toxicological and therapeutic pharmacological substances.
The demand for such specialist analysis has seen a significant rise in the past few years as alcohol, common sedatives and illicit drugs have become more readily available resulting in an increase in the number of reported drug facilitated crimes, in particular for Drug Facilitated Sexual Assaults (DFSA).
Dr Pascal Kintz from Laboratoire ChemTox President of the Society of Hair Testing and past President of the International Association of Forensic Toxicologists said:
“To be recognised on an international level for the quality of our services is extremely encouraging, and we will continue to make quality a priority, especially with the demand for our specialist analysis on the rise”
The ongoing investment into pioneering and developing new testing methodologies provides a valuable tool in helping police forces across the UK combat this growing problem.
This latest development continues the company objectives to provide its customers with the highest levels of quality and safety whilst meeting the demands of regulatory authorities for the submission of court admissible results.
Paul Hackett, Managing Director of Eurofins Forensic Services stresses the importance of this achievement as a demonstration of the company’s continued commitment to deliver the highest quality of service to all its customers.
Eurofins Forensic Services specialises in the provision of forensic DNA and toxicological testing and support services to police, legal, and criminal justice organisations within the UK.
Notes for the editor:
Eurofins – a global leader in bio-analysis
With over 7,000 staff in more than 100 laboratories across 29 countries, Eurofins offers a portfolio of over 25,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by our highly qualified staff.
The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
The shares of Eurofins Scientific are listed on the Euronext Paris (ISIN FR0000038259) and Frankfurt (WKN 910251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).
